Skip to main content

Advertisement

Table 6 Predictive analysis of GR methylation groups

From: Region-specific glucocorticoid receptor promoter methylation has both positive and negative prognostic value in patients with estrogen receptor-positive breast cancer

GR methylation group Treatment # of patients OS DFS
5-year OS Hazard ratio [95% CI] P P value for interaction 5-year DFS Hazard ratio [95% CI] P P value for interaction
C methylated Placebo 27 92.6% 1 0.82 0.427 81.5% 1 0.789 0.723
Tamoxifen 15 93.3% 0.744 [0.058–9.598]   86.7% 1.221 [0.266–5.597]  
Both C and U unmethylated Placebo 62 90.3% 1 0.596 72.6% 1 0.328
Tamoxifen 57 87.5% 1.258 [0.563–2.493]   73.2% 0.755 [0.418–1.361]  
U methylated, no C methylation Placebo 23 65.2% 1 0.105 47.8% 1 0.081
Tamoxifen 22 86.4% 0.414 [0.142–1.203]   68.2% 0.430 [0.166–1.110]  
  1. Hazard ratios are adjusted for age, pathological stage, pathological T-stage, nodal status, and type of adjuvant chemotherapy